Research Summary

My research focus is on the development of novel therapies for patients, as well as the assessment of novel imaging markers of prognosis and response to therapy. As program leader for the Neuro-Oncology Program at the Helen Diller Family Comprehensive Cancer Center, my role is to provide the overall direction of the program and facilitate the interaction of the basic science and translational research programs with the clinical team to bring novel findings from the lab to the patient. I am the lead and contact PI for a P01 focused on integrating advances in physiologic and metabolic imaging with tissue biomarkers in order to optimize the management of patients with molecular subtypes of glioma. I am the overall Clinical Leader for the UCSF Brain SPORE grant as well as the Clinical Core Director and Co-PI of a SPORE project that addresses the evaluation of steady and dynamic metabolic imaging in glioblastoma.

Research Funding

  • July 1, 2021 - June 30, 2026 - Glioblastoma Therapeutics Network , Administrative and Clinical Core Co Investigator . Sponsor: NIH/NCI, Sponsor Award ID: UCA264338A
  • December 1, 2005 - July 31, 2024 - Noninvasive Metabolic Signatures to Improve Management of Molecular Subtypes of Glioma , Principal Investigator . Sponsor: NIH, Sponsor Award ID: P01CA118816
  • September 20, 2002 - August 31, 2023 - Brain Tumor SPORE Grant , Co-Investigator . Sponsor: NIH, Sponsor Award ID: P50CA097257
  • August 5, 1999 - July 31, 2023 - NCI Comprehensive Cancer Center Grant , Program Co-leader . Sponsor: NIH/NCI, Sponsor Award ID: P30 CA082103-17

Education

University of British Columbia, 1981
University of British Columbia, MD, 1985, Medicine
Pasqua Hospital, University of Saskatchewan, Regina, Internship, 1985-1986
Plains Health Centre, Regina, Saskatchewan, Residency, 1986-1987
Toronto General Hospital, U of Toronto, Ontario, Residency, 1987-1989
Princess Margaret Hospital, U of Toronto, Ontario, Residency, 1989-1991
Royal College of Physicians & Surgeons, Canada, FRCPS, 1990, Internal Medicine
Royal College of Physicians & Surgeons, Canada, FRCPS, 1991, Medical Oncology

Honors & Awards

  • 2014
    UCSF Voice of the Patient Pinnacle Award x 7 years, Press Ganey award for excellence in patient care per division, Hall of Fame
  • 2014
    John J. Mealey Jr. Neuro-Oncology Lectureship

Selected Publications

  1. Karschnia P, Dono A, Young JS, Juenger ST, Teske N, Häni L, Sciortino T, Mau CY, Bruno F, Nunez L, Morshed RA, Haddad AF, Weller M, van den Bent M, Beck J, Hervey-Jumper S, Molinaro AM, Tandon N, Rudà R, Vogelbaum MA, Bello L, Schnell O, Grau SJ, Chang SM, Berger MS, Esquenazi Y, Tonn JC. Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group. Neuro Oncol. 2023 Sep 05; 25(9):1672-1685.  View on PubMed
  2. Chang SM. Increasing growth and impact of Neuro-Oncology. Neuro Oncol. 2023 Jul 06; 25(7):1199.  View on PubMed
  3. Ellingson BM, Wen PY, Chang SM, van den Bent M, Vogelbaum MA, Li G, Li S, Kim J, Youssef G, Wick W, Lassman AB, Gilbert MR, de Groot JF, Weller M, Galanis E, Cloughesy TF. Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro Oncol. 2023 06 02; 25(6):1017-1028.  View on PubMed
  4. Karschnia P, Young JS, Dono A, Häni L, Sciortino T, Bruno F, Juenger ST, Teske N, Morshed RA, Haddad AF, Zhang Y, Stoecklein S, Weller M, Vogelbaum MA, Beck J, Tandon N, Hervey-Jumper S, Molinaro AM, Rudà R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, Berger MS, Chang SM, van den Bent M, Tonn JC. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group. Neuro Oncol. 2023 05 04; 25(5):940-954.  View on PubMed
  5. Chang SM. Launch of an Editorial Scholars Program for Neuro-Oncology. Neuro Oncol. 2023 02 14; 25(2):219-220.  View on PubMed
  6. Zhang Y, Lucas CG, Young JS, Morshed RA, McCoy L, Oberheim Bush NA, Taylor JW, Daras M, Butowski NA, Villanueva-Meyer JE, Cha S, Wrensch M, Wiencke JK, Lee JC, Pekmezci M, Phillips JJ, Perry A, Bollen AW, Aghi MK, Theodosopoulos P, Chang EF, Hervey-Jumper SL, Berger MS, Clarke JL, Chang SM, Molinaro AM, Solomon DA. Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro Oncol. 2022 10 03; 24(10):1749-1762.  View on PubMed
  7. Karschnia P, Young JS, Dono A, Häni L, Juenger ST, Sciortino T, Bruno F, Teske N, Morshed RA, Haddad AF, Zhang Y, Stoecklein S, Vogelbaum MA, Beck J, Tandon N, Hervey-Jumper S, Molinaro AM, Rudà R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, van den Bent M, Weller M, Berger MS, Chang SM, Tonn JC. TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO resect group. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac158.  View on PubMed
  8. McKinney AM, Mathur R, Stevers NO, Molinaro AM, Chang SM, Phillips JJ, Costello JF. GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer. Cell Rep. 2022 09 20; 40(12):111344.  View on PubMed
  9. Barger CJ, Suwala AK, Soczek KM, Wang AS, Kim MY, Hong C, Doudna JA, Chang SM, Phillips JJ, Solomon DA, Costello JF. Conserved features of TERT promoter duplications reveal an activation mechanism that mimics hotspot mutations in cancer. Nat Commun. 2022 09 16; 13(1):5430.  View on PubMed
  10. Chang SM. Building on the journal's success through collaboration and partnership. Neuro Oncol. 2022 09 01; 24(9):1407.  View on PubMed
  11. Vaziri S, Autry AW, Lafontaine M, Kim Y, Gordon JW, Chen HY, Hu JY, Lupo JM, Chang SM, Clarke JL, Villanueva-Meyer JE, Bush NAO, Xu D, Larson PEZ, Vigneron DB, Li Y. Assessment of higher-order singular value decomposition denoising methods on dynamic hyperpolarized [1-13C]pyruvate MRI data from patients with glioma. Neuroimage Clin. 2022; 36:103155.  View on PubMed
  12. Lucas CG, Sloan EA, Gupta R, Wu J, Pratt D, Vasudevan HN, Ravindranathan A, Barreto J, Williams EA, Shai A, Whipple NS, Bruggers CS, Maher O, Nabors B, Rodriguez M, Samuel D, Brown M, Carmichael J, Lu R, Mirchia K, Sullivan DV, Pekmezci M, Tihan T, Bollen AW, Perry A, Banerjee A, Mueller S, Gupta N, Hervey-Jumper SL, Oberheim Bush NA, Daras M, Taylor JW, Butowski NA, de Groot J, Clarke JL, Raleigh DR, Costello JF, Phillips JJ, Reddy AT, Chang SM, Berger MS, Solomon DA. Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. Acta Neuropathol. 2022 Oct; 144(4):747-765.  View on PubMed
  13. Autry AW, Lafontaine M, Jalbert L, Phillips E, Phillips JJ, Villanueva-Meyer J, Berger MS, Chang SM, Li Y. Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas. J Neurooncol. 2022 Aug; 159(1):43-52.  View on PubMed
  14. Soffietti R, Bettegowda C, Mellinghoff IK, Warren KE, Ahluwalia MS, De Groot JF, Galanis E, Gilbert MR, Jaeckle KA, Le Rhun E, Rudà R, Seoane J, Thon N, Umemura Y, Weller M, van den Bent MJ, Vogelbaum MA, Chang SM, Wen PY. Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro Oncol. 2022 06 01; 24(6):855-871.  View on PubMed
  15. Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. J Clin Invest. 2022 02 01; 132(3).  View on PubMed
  16. Luks TL, Villanueva-Meyer JE, Weyer-Jamora C, Gehring K, Jakary A, Hervey-Jumper SL, Braunstein SE, Bracci PM, Brie MS, Smith EM, Chang SM, Taylor JW. T2 FLAIR Hyperintensity Volume Is Associated With Cognitive Function and Quality of Life in Clinically Stable Patients With Lower Grade Gliomas. Front Neurol. 2021; 12:769345.  View on PubMed
  17. Aabedi AA, Young JS, Zhang Y, Ammanuel S, Morshed RA, Dalle Ore C, Brown D, Phillips JJ, Oberheim Bush NA, Taylor JW, Butowski N, Clarke J, Chang SM, Aghi M, Molinaro AM, Berger MS, Hervey-Jumper SL. Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. Neurosurgery. 2022 01 01; 90(1):124-130.  View on PubMed
  18. Lucas CG, Gupta R, Wu J, Shah K, Ravindranathan A, Barreto J, Gener M, Ginn KF, Prall OWJ, Xu H, Kee D, Ko HS, Yaqoob N, Zia N, Florez A, Cha S, Perry A, Clarke JL, Chang SM, Berger MS, Solomon DA. EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma. Acta Neuropathol. 2022 01; 143(1):109-113.  View on PubMed
  19. Gupta R, Lucas CG, Wu J, Barreto J, Shah K, Simon IB, Casavilca-Zambrano S, Brathwaite C, Zhou H, Caccamo D, Gilani A, Kleinschmidt-DeMasters BK, Lee JC, Perry A, Clarke JL, Chang SM, Berger MS, Solomon DA. Low-grade glioneuronal tumors with FGFR2 fusion resolve into a single epigenetic group corresponding to 'Polymorphous low-grade neuroepithelial tumor of the young'. Acta Neuropathol. 2021 09; 142(3):595-599.  View on PubMed
  20. Bush NAO, Young JS, Zhang Y, Dalle Ore CL, Molinaro AM, Taylor J, Clarke J, Prados M, Braunstein SE, Raleigh DR, Chang SM, Berger MS, Butowski NA. A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. J Neurooncol. 2021 Jul; 153(3):447-454.  View on PubMed

Go to UCSF Profiles, powered by CTSI